DICLOFENAC SODIUM AND MISOPROSTOL tablet, delayed release

Страна: Соединенные Штаты

Язык: английский

Источник: NLM (National Library of Medicine)

Активный ингредиент:

DICLOFENAC SODIUM (UNII: QTG126297Q) (DICLOFENAC - UNII:144O8QL0L1), MISOPROSTOL (UNII: 0E43V0BB57) (MISOPROSTOL - UNII:0E43V0BB57)

Доступна с:

Actavis Pharma, Inc.

ИНН (Международная Имя):

DICLOFENAC SODIUM

состав:

DICLOFENAC SODIUM 50 mg

Администрация маршрут:

ORAL

Тип рецепта:

PRESCRIPTION DRUG

Терапевтические показания :

Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications [see Warnings and Precautions (5.3) ]. Diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: - Pregnancy. Use of misoprostol, a component of diclofenac sodium and misoprostol delayed-release tablets, during pregnancy can result in maternal and fetal harm, including uterine rupture, abortion, premature birth, or birth defects [see Warnings and Precautions (5.1)  and Use in Specific Populations (8.1) ] - In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.2) ] - Active gastrointestinal bleeding [see Warnings and Precautions (5.3)] - History

Обзор продуктов:

Diclofenac sodium and misoprostol delayed-release tablets, USP are supplied as:  The dosage strengths are supplied in: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Статус Авторизация:

Abbreviated New Drug Application

тонкая брошюра

Actavis Pharma, Inc.
----------
MEDICATION GUIDE
Diclofenac Sodium (dye kloe' fen ak soe' dee um) and Misoprostol
(mye'' soe pros' tol)
Delayed-Release Tablets
for oral use
What is the most important information I should know about diclofenac
sodium and misoprostol delayed-release tablets?
Diclofenac sodium and misoprostol delayed-release tablets contain
diclofenac (a nonsteroidal anti-inflammatory drug (NSAID)) and
misoprostol, and can
cause uterus to tear (uterine rupture), abortion, premature birth, or
birth defects. The risk of uterine rupture increases as your pregnancy
advances, if you
have given birth to 5 or more children, and if you have had surgery on
the uterus, such as a cesarean delivery.
Do not take diclofenac sodium and misoprostol delayed-release tablets
if you are pregnant.
•
Tell your healthcare provider if you become pregnant or think you may
be pregnant during treatment with diclofenac sodium and misoprostol
delayed-release tablets. If you are able to become pregnant, your
healthcare provider should do a pregnancy test before you start
treatment with
diclofenac sodium and misoprostol delayed-release tablets. Females who
are able to become pregnant should use an effective form of birth
control
(contraception) during treatment with diclofenac sodium and
misoprostol delayed-release tablets.
What is the most important information I should know about medicines
containing Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?
NSAIDs can cause serious side effects, including:
•
Increased risk of a heart attack or stroke that can lead to death.
This risk may happen early in treatment and may increase:
•
with increasing doses of NSAIDs
•
with longer use of NSAIDs
Do not take NSAID containing medicines right before or after a heart
surgery called a “coronary artery bypass graft (CABG)."
Avoid taking NSAID containing medicines after a recent heart attack,
unless your healthcare provider tells you to. You may have an
increased risk of
another heart attack if you take NSAIDs after a recent heart attack.

Характеристики продукта

DICLOFENAC SODIUM AND MISOPROSTOL- DICLOFENAC SODIUM AND
MISOPROSTOL TABLET, DELAYED RELEASE
ACTAVIS PHARMA, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
DICLOFENAC SODIUM
AND MISOPROSTOL DELAYED-RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE
FULL PRESCRIBING
INFORMATION FOR DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE
TABLETS.
DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE TABLETS, FOR ORAL
USE
INITIAL U.S. APPROVAL: 1997
WARNING: RISK OF UTERINE RUPTURE, ABORTION, PREMATURE BIRTH, BIRTH
DEFECTS;
SERIOUS CARDIOVASCULAR EVENTS; AND SERIOUS GASTROINTESTINAL EVENTS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
ADMINISTRATION OF MISOPROSTOL, A COMPONENT OF DICLOFENAC SODIUM AND
MISOPROSTOL
DELAYED-RELEASE TABLETS, TO PREGNANT WOMEN CAN CAUSE UTERINE RUPTURE,
ABORTION,
PREMATURE BIRTH, OR BIRTH DEFECTS. UTERINE RUPTURE HAS OCCURRED WHEN
MISOPROSTOL
WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR AN ABORTION. (4,
5.1, 8.1)
DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE TABLETS ARE
CONTRAINDICATED IN
PREGNANCY AND ARE NOT RECOMMENDED IN WOMEN OF CHILDBEARING POTENTIAL.
PATIENTS
MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE
THE DRUG TO
OTHERS. (5.1, 8.3)
INCREASED RISK OF SERIOUS CARDIOVASCULAR THROMBOTIC EVENTS, INCLUDING
MYOCARDIAL
INFARCTION AND STROKE, WHICH CAN BE FATAL. (5.2)
DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE TABLETS ARE
CONTRAINDICATED IN
THE SETTING OF CORONARY ARTERY BYPASS GRAFT (CABG) SURGERY. (4, 5.2) INCREASED RISK OF SERIOUS GASTROINTESTINAL (GI) ADVERSE EVENTS
INCLUDING BLEEDING,
ULCERATION, AND PERFORATION OF THE STOMACH OR INTESTINES, WHICH CAN BE
FATAL AND CAN
OCCUR AT ANY TIME AND WITHOUT WARNING SYMPTOMS. ELDERLY PATIENTS AND
PATIENTS WITH
A PRIOR HISTORY OF PEPTIC ULCER DISEASE AND/OR GI BLEEDING ARE AT
GREATER RISK. (5.3)
INDICATIONS AND USAGE
Diclofenac sodium and misoprostol delayed-release tablets are a
combination of diclofenac sodium, a
non-steroidal